Top Medical Exoskeleton Companies

Global Medical Exoskeleton Market size was valued at USD 457.11 Million in 2024 and is poised to grow from USD 534.36 Million in 2025 to USD 1863.59 Million by 2033, growing at a CAGR of 16.9% during the forecast period (2026–2033).

The global medical exoskeleton industry is witnessing moderate-to-high growth owing to rising investment in the advancement of technology related to exoskeletons, high adoption rate of exoskeletons in healthcare sector, and insurance coverage for exoskeletons. Due to the advent of processes such as robotics and artificial intelligence technology, a high amount of innovation is expected. The current market players are constantly developing new and innovative applications of exoskeletons, which is creating novel paths for them in the coming years. Apart from this, the growth of the market is expected to be positively influenced by a well-developed regulatory framework and increasing approval of exoskeleton products from these regulatory bodies.  'CYBERDYNE Inc. (Japan) ', 'Ekso Bionics (US) ', 'Ergosante (France) ', 'B-Temia (Canada) ', 'ExoAtlet (Luxembourg) ', 'ReWalk Robotics (Israel) ', 'Ottobock SE & Co. KGaA (Germany) ', 'DIH Medical/Hocoma (Switzerland) ', 'Human Motion Technologies LLC. (US) ', 'Wearable Robotics srl (Italy) ', 'Myomo Inc. (US) ', 'Lifeward Ltd. (Israel) ', 'Hyundai Motor Group Robotics LAB. (South Korea) ', 'ABLE Human Motion (Spain) ', 'Laevo Exoskeletons (Netherlands) ', 'German Bionic Systems GmbH (Germany) ', 'Fourier (China) ', 'Levitate Technologies, Inc. (US) ', 'Gogoa Mobility Robots SL (Spain)'

The burgeoning geriatric population has resulted in an increase of disablements as the aged are more likely to have ailments such a stroke and severe musculoskeletal injuries due falls. Hence, the demand for functional rehabilitation methods using various technologies and products is rapidly growing around the world. Such factors are considered a perfect indicator for the growth in the medical exoskeleton market size in all crucial regions.

Many rehabilitation centers in several countries also use augmentative device like exoskeletons. However, numerous countries are seeing low insurance coverage for the exoskeleton technology. Hence, the MNCs are currently concentrating on formulating policies and signing strategic partnerships and contracts with several public-and private-schemes of insurance payer to reimburse medical exoskeleton devices.

North America dominated the market with an increasing medical exoskeleton market share in 2023. This growth is due to increasing research activities expenditure, high prevalence of disabled population, rising partnerships & collaborations among key players, availability of technologically innovated products and growing public & private funding. An example would be the collaboration between Ekso Bionics, which develops exoskeleton technology to assist in care for patients with mobility issues, and U.S. Physiatry (USP) in March 2021. They joined forces to empower clinicians or physicians with knowledge of how the clinical benefits of an EksoNR exoskeleton can improve at their centers. In addition, increasing disposable income, rising geriatric population, presence of key market players at large scale, growing human augmentation in industrial and military verticals and availability of public & private investors are some other factors propelling the growth.